BioTech IP Review

RNA-Based Therapeutics & Regulation

What’s emerging

  • mRNA beyond vaccines
  • siRNA, antisense, circular RNA
  • RNA editing and RNA regulation

Why it’s promising

  • Modularity and rapid design cycles
  • Expanding delivery solutions

IP significance

  • Delivery remains the dominant value driver
  • Claims increasingly tied to chemical modification + formulation
  • Crowded prior art landscape, but still room for defensible niches

Leave a comment